Image

Effect of Left Posterior Pericardiotomy for the Prevention of POAF

Effect of Left Posterior Pericardiotomy for the Prevention of POAF

Recruiting
19 years and older
All
Phase N/A

Powered by AI

Overview

This study is planned to evaluate the effect of left posterior pericardiotomy for the prevention of postoperative atrial fibrillation after coronary artery bypass grafting. Eligible patients will be randomized to be created or not to be created the left posterior pericardiotomy at the end of the operation, and the incidence of postoperative atrial fibrillation will be compared.

Description

Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery, particularly after coronary artery bypass grafting (CABG), and is associated with prolonged in-hospital stay and increased adverse outcomes, including death and stroke. There is evidence that pericardial effusion can trigger the occurence of POAF. Therefore, this study is aimed to evaluate the effect of left posterior pericardiotomy for the prevention of POAF after CABG.

Patients who are planned to undergo off-pump CABG will be randomized to be created or not to be created the left posterior pericardiotomy at the end of the operation, and the incidence of postoperative atrial fibrillation will be compared as the primary outcome. Secondary outcomes will include early clinical outcomes and hospital stay.

Eligibility

Inclusion Criteria:

  • patients who are planned to undergo coronary artery bypass grafting
  • patients aged ≥19 years

Exclusion Criteria:

  • patients who are planned to undergo other concomitant cardiac procedures (e.g. valve procedures, aorta procedures)
  • patients who undergo coronary artery bypass grafting using cardiopulmonary bypass
  • patients who are documented with paroxysmal, persistent, or permanent atrial fibrillation before operation
  • patients who have a history of cardiac surgery
  • patients who have a history of pericardial disease
  • patients who have severe adhesion at left pleural cavity which precludes effective left posterior pericardiostomy
  • patients who refuse to participate in this study

Study details
    Coronary Artery Disease
    Atrial Fibrillation New Onset
    Pericardial Effusion

NCT06159985

Seoul National University Hospital

1 May 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.